The role of B7 family molecules in hematologic malignancy

被引：164

作者：

Greaves, Paul ^{[1
]}

Gribben, John G. ^{[1
]}

机构：

[1] Queen Mary Univ London, Barts Canc Inst, London, England

来源：

BLOOD | 2013年 / 121卷 / 05期

关键词：

REGULATORY T-CELLS; VERSUS-HOST-DISEASE; INDUCED KILLER-CELLS; ANTI-CD80; MONOCLONAL-ANTIBODY; CHRONIC LYMPHOCYTIC-LEUKEMIA; INDUCIBLE COSTIMULATOR ICOS; COLONY-STIMULATING FACTOR; CXC CHEMOKINE RECEPTOR-5; REED-STERNBERG CELLS; IN-VIVO EXPRESSION;

D O I：

10.1182/blood-2012-10-385591

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The B7 family consists of structurally related, cell-surface proteins that regulate immune responses by delivering costimulatory or coinhibitory signals through their ligands. Eight family members have been identified to date including CD80 (B7-1), CD86 (B7-2), CD274 (programmed cell death-1 ligand [PD-L1]), CD273 (programmed cell death-2 ligand [PD-L2]), CD275 (inducible costimulator ligand [ICOS-L]), CD276 (B7-H3), B7-H4, and B7-H6. B7 ligands are expressed on both lymphoid and nonlymphoid tissues. The importance of the B7 family in regulating immune responses is clear from their demonstrated role in the development of immunodeficiency and autoimmune diseases. Manipulation of the signals delivered by B7 ligands shows great potential in the treatment of cancers including leukemias and lymphomas and in regulating allogeneic T-cell responses after stem cell transplantation. (Blood. 2013;121(5):734-744)

引用

页码：734 / 744

页数：11

共 201 条

[31] Phase I/II study of galiximab, an Anti-CD80 antibody, for relapsed or refractory follicular lymphoma [J].